U.S. drugmaker Merck & Co. Inc. on May 21 agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.
The acquisition can strengthen Merck’s presence in the field of renal cell carcinoma and bolster its cancer drug portfolio.
